These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 33202447)

  • 1. Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
    Ageno W; Vedovati MC; Cohen A; Huisman M; Bauersachs R; Gussoni G; Becattini C; Agnelli G
    Thromb Haemost; 2021 May; 121(5):616-624. PubMed ID: 33202447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
    Cohen AT; Creeper KJ; Alikhan R; Er C; Connors JM; Huisman MV; Munoz A; Vescovo G; Bauersachs R; Ageno W; Agnelli G; Becattini C
    Thromb Haemost; 2024 Jul; 124(7):676-683. PubMed ID: 38196077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
    Agnelli G; Becattini C; Meyer G; Muñoz A; Huisman MV; Connors JM; Cohen A; Bauersachs R; Brenner B; Torbicki A; Sueiro MR; Lambert C; Gussoni G; Campanini M; Fontanella A; Vescovo G; Verso M;
    N Engl J Med; 2020 Apr; 382(17):1599-1607. PubMed ID: 32223112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study.
    Agnelli G; Becattini C; Bauersachs R; Brenner B; Campanini M; Cohen A; Connors JM; Fontanella A; Gussoni G; Huisman MV; Lambert C; Meyer G; Muñoz A; Abreu de Sousa J; Torbicki A; Verso M; Vescovo G;
    Thromb Haemost; 2018 Sep; 118(9):1668-1678. PubMed ID: 30103252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
    Agnelli G; Muñoz A; Franco L; Mahé I; Brenner B; Connors JM; Gussoni G; Hamulyak EN; Lambert C; Suero MR; Bauersachs R; Torbicki A; Becattini C
    Thromb Haemost; 2022 May; 122(5):796-807. PubMed ID: 34530482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial.
    Becattini C; Bauersachs R; Maraziti G; Bertoletti L; Cohen A; Connors JM; Manfellotto D; Sanchez A; Brenner B; Agnelli G
    Haematologica; 2022 Jul; 107(7):1567-1576. PubMed ID: 34382385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism.
    Verso M; Munoz A; Bauersachs R; Huisman MV; Mandalà M; Vescovo G; Becattini C; Agnelli G
    Eur J Cancer; 2021 May; 148():371-381. PubMed ID: 33780665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.
    Monreal M
    Thromb Haemost; 2018 Nov; 118(11):1850-1851. PubMed ID: 30332697
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study.
    Giustozzi M; Connors JM; Ruperez Blanco AB; Szmit S; Falvo N; Cohen AT; Huisman M; Bauersachs R; Dentali F; Becattini C; Agnelli G
    J Thromb Haemost; 2021 Nov; 19(11):2751-2759. PubMed ID: 34260816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
    McBane RD; Wysokinski WE; Le-Rademacher JG; Zemla T; Ashrani A; Tafur A; Perepu U; Anderson D; Gundabolu K; Kuzma C; Perez Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Houghton DE; Vishnu P; Loprinzi CL
    J Thromb Haemost; 2020 Feb; 18(2):411-421. PubMed ID: 31630479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
    J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban for extended treatment of venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Porcari A; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Feb; 368(8):699-708. PubMed ID: 23216615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
    Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.
    Kraaijpoel N; Di Nisio M; Mulder FI; van Es N; Beyer-Westendorf J; Carrier M; Garcia D; Grosso M; Kakkar AK; Mercuri MF; Middeldorp S; Hernandez CR; Santamaria A; Schwocho L; Segers A; Verhamme P; Wang TF; Weitz JI; Zhang G; Zwicker JI; Büller HR; Raskob GE
    Thromb Haemost; 2018 Aug; 118(8):1439-1449. PubMed ID: 30060256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
    Arce-Huamani MA; Barboza JJ; Martínez-Herrera JF; Torres-Roman JS; Maguiña JL
    Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893585
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
    Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
    Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study.
    Verso M; Agnelli G; Munoz A; Connors JM; Sanchez O; Huisman M; Brenner B; Gussoni G; Cohen AT; Becattini C
    Eur J Cancer; 2022 Apr; 165():136-145. PubMed ID: 35235870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
    Levine MN; Gu C; Liebman HA; Escalante CP; Solymoss S; Deitchman D; Ramirez L; Julian J
    J Thromb Haemost; 2012 May; 10(5):807-14. PubMed ID: 22409262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.